Latest news with #RelonchemLimited
&w=3840&q=100)
Business Standard
15 hours ago
- Business
- Business Standard
Marksans Pharma gains 3% on UK MHRA approval for subsidiary; details here
Marksans Pharma share price: Shares of pharmaceutical company Marksans Pharma were trading higher during intra-day deals on Monday, August 18, 2025. The company's share price rose 3.37 per cent to log an intra-day high of ₹184.60 per share on the National Stock Exchange (NSE). The pharmaceutical stock continued to trade higher on the bourses. At last check, Marksans Pharma shares were quoted at ₹183.27 per share, up 2.63 per cent from the previous close of ₹178.58 on the NSE. A combined total of 0.13 million equity shares of Marksans Pharma, estimated to be valued at ₹24.37 crore, exchanged hands on the NSE and BSE today. Why are Marksans Pharma shares ruling higher on the bourses? The upward movement in Marksans Pharma's share price came after the company announced that its wholly owned subsidiary, Relonchem Limited in the UK, had received marketing authorisation for three of its products. "Our wholly owned subsidiary, Relonchem Limited in the UK, has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (UK MHRA) for the following products: Metformin Hydrochloride Relonchem 500 mg Prolonged Release Tablets, Metformin Hydrochloride Relonchem 750 mg Prolonged Release Tablets, and Metformin Hydrochloride Relonchem 1000 mg Prolonged Release Tablets," Marksans Pharma said in a release. About Marksans Pharma Headquartered in Mumbai, Marksans Pharma is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations in global markets. The company's key focus areas lie in both over-the-counter (OTC) and prescription drugs, with wide-ranging applications across therapeutic areas such as pain management, cough and cold, digestive health, cardiovascular (CVS), central nervous system (CNS), oncology, antidiabetics, and antibiotics, among others. Marksans Pharma's manufacturing facilities in India, the USA, and the UK are approved by several leading regulatory agencies, including the USFDA, UK MHRA, and Australian TGA. Its product portfolio spans major therapeutic segments such as CVS, CNS, anti-diabetic, pain management, gastroenterology, and antiallergics. The company markets its products globally. As of August 18, 2025, the pharmaceutical company had a market capitalisation of ₹8,325.07 crore on the NSE. Marksans Pharma share price history Shares of Marksans Pharma have declined nearly 39 per cent year-to-date (YTD). In contrast, the benchmark Nifty50 has advanced nearly 5 per cent during the same period. Marksans Pharma shares hit their 52-week high of ₹358.70 per share on the NSE on August 28, 2024, while the 52-week low of ₹171 was recorded on April 7, 2024.
Business Upturn
18 hours ago
- Business
- Business Upturn
Marksans Pharma's UK subsidiary Relonchem secures marketing authorization from MHRA for Metformin tablets
Marksans Pharma Limited (NSE: MARKSANS, BSE: 524404) announced that its wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for three key anti-diabetic products. The approvals cover: Metformin Hydrochloride Relonchem 500 mg Prolonged Release Tablets Metformin Hydrochloride Relonchem 750 mg Prolonged Release Tablets Metformin Hydrochloride Relonchem 1000 mg Prolonged Release Tablets Metformin is among the most widely prescribed medications for the treatment of type 2 diabetes, playing a crucial role in blood sugar management. With this authorization, Relonchem will be able to expand its presence in the UK market and further strengthen Marksans Pharma's position in the global anti-diabetic segment. Headquartered in Mumbai, Marksans Pharma operates manufacturing facilities in India, the USA, and the UK, all of which are approved by global regulators including USFDA, UKMHRA, and TGA. The company has a diversified product portfolio spanning cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterology, and anti-allergy therapies. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
19-06-2025
- Business
- Business Upturn
Marksans Pharma's UK subsidiary secures approval for Oxybutynin Hydrochloride oral solution
By Aditya Bhagchandani Published on June 19, 2025, 09:14 IST Marksans Pharma Limited announced today that its wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorization for Oxybutynin Hydrochloride 2.5mg/5ml Oral Solution from the UK's Medicines & Healthcare Products Regulatory Agency (MHRA). The product, used primarily for treating overactive bladder and urinary incontinence, expands Marksans' offering in the urology therapeutic segment and strengthens its European portfolio. The company, headquartered in Mumbai, manufactures and markets generic pharmaceutical formulations globally, with facilities in India, the US, and the UK—approved by regulatory bodies including the USFDA, UKMHRA, and Australia's TGA. 'This approval further reinforces our commitment to expanding our presence in regulated markets through high-quality generic products,' the company said in a press release. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
30-05-2025
- Business
- Business Upturn
Marksans Pharma's subsidiary Relonchem gets UK MHRA approval for Metformin Hydrochloride Oral Solution
By Aman Shukla Published on May 30, 2025, 09:24 IST Marksans Pharma Limited has announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Metformin Hydrochloride 500mg/5ml Oral Solution. This regulatory approval enables Relonchem to market and distribute the product in the UK. Metformin Hydrochloride is a widely prescribed medication used for the management of type 2 diabetes, particularly in patients who require oral liquid formulations due to difficulty in swallowing tablets. In the exchange filing, the company shared, 'Marksans Pharma Limited (Reuters: Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Metformin Hydrochloride 500mg/ 5 ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.' This approval marks a significant milestone for Marksans Pharma as it continues to strengthen its presence in regulated markets like the UK. The company's focus on expanding its product portfolio with value-added generic formulations aligns with its strategic growth vision. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
19-05-2025
- Business
- Business Upturn
Marksans Pharma's UK arm gets marketing approval for Sennosides 7.5 mg tablets
By Aditya Bhagchandani Published on May 19, 2025, 13:27 IST Shares of Marksans Pharma could remain in focus after the company announced that its wholly owned UK subsidiary, Relonchem Limited, has received marketing authorization for Sennosides 7.5 mg tablets from the UK Medicines & Healthcare Products Regulatory Agency (MHRA). This regulatory clearance marks a significant step in the company's product expansion in the UK pharmaceutical market. Sennosides are typically used as a laxative in various therapeutic segments, and the approval strengthens Marksans' position in the gastrointestinal treatment category. Marksans Pharma, headquartered in Mumbai, engages in the research, manufacturing, and marketing of generic pharmaceutical formulations across global markets. Its manufacturing facilities in India, the USA, and the UK are approved by top regulatory bodies, including USFDA, UKMHRA, and Australian TGA. The company's product portfolio spans major therapeutic areas such as cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterological, and anti-allergies. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
